Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0343 • ACR Convergence 2020
Co-expression of DC-STAMP and CX3CR1: Biomarkers for Tissue Resident Osteoclasts in Psoriatic Arthritis
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno², Ananta Paine³, Benjamin Korman³, Marc Nuzzo⁴, Lihi Eder⁵ and Christopher Ritchlin³, ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY, ³Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁴Department of Medicine, University of Rochester Medical Center, Rochester, ⁵Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) patients often experience joint damage mediated by osteoclasts (OC). Although PsA pathogenesis is poorly understood, the production of the cytokines IL-17,…
Abstract Number: 0368 • ACR Convergence 2020
Comparable Impact and Burden of Disease of Psoriatic Arthritis Patients with Limited Joint Involvement vs. Those with More Extensive Joint Involvement: Interim Results from a Prospective, Multicenter, Real-World Study in Patients Treated with Apremilast
Tim Jansen¹, Arie van Vliet² and Marijn Vis³, ¹Viecuri MC, Venlo, Netherlands, ²Amgen B.V., Breda, Netherlands, ³Erasmus UMC, Rotterdam, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is associated with a high burden of disease and an increased risk of comorbidities. Recent data suggest that patients with moderate…
Abstract Number: 0505 • ACR Convergence 2020
Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial
Xenofon Baraliakos¹, Laure Gossec², Effie Pournara³, Slawomir Jeka⁴, Ricardo Blanco⁵, Salvatore D'Angelo⁶, Georg Schett⁷, Barbara Schulz³, Michael Rissler³, Dermot Whyms⁸, Chiara Perella³ and Laura Coates⁹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Novartis Pharma AG, Basel, Switzerland, ⁴2nd Univ Hospital, CM UMK, Bydgoszcz, Poland, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁶Rheumatology Department of Lucania and Rheumatology Institute of Lucania (IRel), San Carlo Hospital of Potenza, Potenza, Italy, ⁷Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁸Novartis Ireland Limited, Dublin, Ireland, ⁹University of Oxford, Oxford, United Kingdom
Background/Purpose: Axial disease may affect up to 25–70% of psoriatic arthritis (PsA) patients, depending on the definition used. Current evidence on efficacy of biologics in…
Abstract Number: 0894 • ACR Convergence 2020
Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study
Stanley Cohen¹, Justus Fiechtner², Philip Mease³, Jeffrey Kaine⁴, Arthur Kavanaugh⁵, Yi-Lin (Irene) Cheng⁶, Claire Chou⁶, Ting-Ying Cheng⁷, Shih-Yao Lin⁶ and Mark Genovese⁸, ¹University of Texas Southwestern Medical School at Dallas, and Metroplex Clinical Research Center, Dallas, TX, ²Michigan State University, Grand Rapids,, MI, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴Sarasota Arthritis Research Center, Sapphire, NC, ⁵UC San Diego Health System, San Diego, CA, ⁶AltruBio, Taipei, Taiwan (Republic of China), ⁷AltruBio, Redwood City, CA, ⁸Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.…
Abstract Number: 1031 • ACR Convergence 2020
Real World Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Ixekizumab
Mwangi Murage¹, Nicole Princic², Julie Park², William Malatestinic¹, Baojin Zhu¹, Bilal Atiya¹, Scott Kern¹, Keri Stenger¹, Aubrey Sprabery¹ and Alexis Ogdie³, ¹Eli Lilly and Company, Indianapolis, IN, ²IBM Watson Health, Cambridge, MA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a systemic condition estimated to affect 0.05%-0.25% of the United States (US)1 population. With approval of ixekizumab (a selectively binding…
Abstract Number: 1345 • ACR Convergence 2020
Upadacitinib as Monotherapy and in Combination with Non-biologic DMARDs for the Treatment of Psoriatic Arthritis: Subgroup Analysis from Two Phase 3 Trials
Peter Nash¹, Pascal Richette², Laure Gossec³, Antonio Marchesoni⁴, Koji Kato⁵, Erin Blondell⁶, Elizabeth Lesser⁶, Reva M McCaskill⁶, Dai Feng⁶, Jaclyn K Anderson⁶ and Eric Ruderman⁷, ¹School of Medicine Griffith University, Brisbane, Queensland, Australia, ²Department of Rheumatology, Lariboisière Hospital, Paris, France, ³Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ⁴ASST Gaetano Pini-CTO, Milano, Italy, ⁵AbbVie Inc, North Chicago, IL, ⁶AbbVie Inc., North Chicago, IL, ⁷Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Approximately 40% of PsA patients (pts) on advanced therapy are on monotherapy.1,2 Upadacitinib (UPA) has shown efficacy and safety in pts with active PsA…
Abstract Number: 1400 • ACR Convergence 2020
cAMP Response Element Modulator (CREM)α Promotes PD-1- effector CD4+ T Cells in Psoriasis and Psoriatic Arthritis
Sigrun Hofmann¹, Franz Kapplusch², Susanne Abraham³, Sarah Northey², Susanne Russ¹, Felix Schulze¹, Anna Surace⁴ and Christian Hedrich⁵, ¹Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany., Dresden, Germany, ²Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Liverpool, United Kingdom, ³Klinik und Poliklinik für Dermatologie, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany., Dresden, Germany, ⁴Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, Liverpool, United Kingdom, ⁵University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Psoriasis is a systemic autoimmune/inflammatory condition that primarily affects the skin, but also other organ systems. Effector CD4+ T lymphocytes have been identified as…
Abstract Number: 1854 • ACR Convergence 2020
NGF/TrkA System Regulates Pain and the Pannus Formation: Targeting NGF-TrkA in Psoriatic Arthritis
Siba Raychaudhuri¹ and Smriti Raychaudhuri², ¹UC Davis, School of Medicine, Davis, CA, ²VA Sacramento Medical Center, Davis, CA
Background/Purpose: Function of Nerve Growth Factor (NGF) in the nervous system and its regulatory role in pain is well defined. We have shown earlier that…
Abstract Number: 0075 • ACR Convergence 2020
CD209+/CD14+ Dendritic Cells Characterization in Rheumatoid versus Psoriasis Arthritis Patients
Viviana Marzaioli¹, Achilleas Floudas², Mary Canavan¹, Siobhán Wade³, Kieran Murray⁴, Ronan Mullan⁵, Conor Hurson⁶, Douglas Veale⁷ and Ursula Fearon¹, ¹Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, ²Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Dublin, Ireland, ³Trinity College Dublin, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, ⁵Adelaide and Meath Hospital, Dublin, Dublin, Ireland, ⁶St Vincents University Hospital, UCD, Dublin, Dublin, Ireland, ⁷EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland
Background/Purpose: Dendritic cells (DCs) are a heterogeneous population of professional antigen-presenting cells which are at the interface between innate and adaptive immunity. There are different…
Abstract Number: 0310 • ACR Convergence 2020
The Prediction of Psoriatic Arthritis Tool (PRESTO) Study – Interim Report
Lihi Eder¹, Ker-Ai Lee², Vinod Chandran³, Jessica Widdifield⁴, Aaron Drucker⁵, Christopher Ritchlin⁶, Cheryl Rosen⁷, Richard Cook² and Dafna Gladman³, ¹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto - Toronto, Toronto, ON, Canada, ⁵University of Toronto, Toronto, Canada, ⁶Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall…
Abstract Number: 0326 • ACR Convergence 2020
Flares Among Patients with Psoriatic Arthritis (PsA) – Frequency and Impact on Patient Outcomes: Real-world Survey in the US and Europe
Ana-Maria Orbai¹, William Tillett², Suzann Grieb³, James Piercy⁴, Steven Peterson⁵, Elizabeth Holdsworth⁴, Sophie Meakin⁴, Soumya Chakravarty⁶, Nicola Booth⁴ and Laure Gossec⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ³John Hopkins University School of Medicine, Baltimore, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France
Background/Purpose: Flares in PsA, presenting as periods of acute disease activity, are thought to negatively impact patients’ lives. This has not been extensively studied in…
Abstract Number: 0344 • ACR Convergence 2020
Use of the BASDAI in Psoriatic Arthritis Patients with and Without Axial Disease
Soumya Reddy¹, M. Elaine Husni², Jose Scher³, Ethan Craig⁴, Alexis Ogdie⁴ and Jessica Walsh⁵, ¹NYU School of Medicine, New York, NY, ²Cleveland Clinic, Cleveland, OH, ³NYU School of Medicine, New York City, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is increasingly being used to assess the activity of axial disease in patients with psoriatic arthritis…
Abstract Number: 0370 • ACR Convergence 2020
Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic Arthritis Trial DISCOVER 1
Ana-Maria Orbai¹, Laura Coates², Atul Deodhar³, Philip Helliwell⁴, Christopher Ritchlin⁵, Alexa Kollmeier⁶, Elizabeth Hsia⁷, Xie Xu⁸, Shihong Sheng⁹, Bei Zhou⁹ and Chenglong Han⁹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Oxford, Oxford, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁶Janssen Research & Development, LLC, La Jolla, CA, ⁷Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁸Janssen Research & Development, LLC, San Marcos, CA, ⁹Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Patients with psoriatic arthritis (PsA) experience broad systemic symptoms including pain, fatigue, depression, sleep disturbance, poor physical function, and diminished social participation. DISCOVER 1…
Abstract Number: 0506 • ACR Convergence 2020
Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through Week 52 of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Iain McInnes¹, Proton Rahman², Alice Gottlieb³, Elizabeth Hsia⁴, Alexa Kollmeier⁵, Xie Xu⁶, Ramanand Subramanian⁷, Prasheen Agarwal⁷, Shihong Sheng⁷, Yusang Jiang⁷, Bei Zhou⁷, Désirée van der Heijde⁸ and Philip Mease⁹, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ³Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁵Janssen Research & Development, LLC, La Jolla, CA, ⁶Janssen Research & Development, LLC, San Marcos, CA, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Guselkumab (GUS), a monoclonal antibody that specifically binds to the p19-subunit of IL-23, is approved to treat psoriasis. Through Week24 (W24) of the Ph3,…
Abstract Number: 0895 • ACR Convergence 2020
Effects of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19-Subunit of Interleukin-23, on Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Pooled Results Through Week 24 from Two Phase 3 Studies
Dennis McGonagle¹, Iain McInnes², Atul Deodhar³, Georg Schett⁴, Philip Mease⁵, May Shawi⁶, Shelly Kafka⁷, Chetan Karyekar⁸, Alexa Kollmeier⁹, Elizabeth Hsia¹⁰, Xie Xu¹¹, Shihong Sheng¹², Prasheen Agarwal¹², Bei Zhou¹², Christopher Ritchlin¹³ and Proton Rahman¹⁴, ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁵Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁶Janssen Global Services, LLC, Toronto, ON, Canada, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Global Services, LLC, Horsham, PA, ⁹Janssen Research & Development, LLC, La Jolla, CA, ¹⁰Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ¹¹Janssen Research & Development, LLC, San Marcos, CA, ¹²Janssen Research & Development, LLC, Spring House, PA, ¹³Department of Medicine, University of Rochester Medical Center, Rochester, NY, ¹⁴Memorial University of Newfoundland, Department of Medicine, St John's, Canada
Background/Purpose: Guselkumab (GUS), a novel monoclonal antibody that specifically binds to the p19-subunit of IL-23, demonstrated efficacy in the Ph 3 DISCOVER-1 (D1) & DISCOVER‑2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].